Review



primary nk cells t2 cell line  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 97
      Buy from Supplier

    Structured Review

    ATCC primary nk cells t2 cell line
    The design and antitumor ability of chimeric TCR (TCR-28-2B10/BBζ) engineered NK-92 cells A, The chimeric TCR (TCR-28-2B10/BBζ) consisted of the extracellular domains of the TCR α and β chains specific for <t>the</t> <t>HLA-A2-restricted</t> NYESO-1-derived “SLLMWITQV” epitope (NYESO-1157-165 V) fused to the CD28 transmembrane domain (TM) followed by the 2B4 costimulatory domain and DAP10 signaling domain as well as the 41BB costimulatory domain and CD3ζ signaling domains, respectively. B, Representative flow cytometry of transduction efficiencies measured by staining chimeric TCR NK-92 cells and TCR NK-92 cells with an anti-murine TCR- β chain constant region antibody. C, IFN- γ ELISA measurement after coculture of chimeric TCR NK-92 cells and NK-92 cells with NYESO-1157-165 V epitope pulsed <t>T2</t> cells. D, IFN- γ ELISA measurement after coculture of chimeric TCR NK-92 cells and NK-92 cells with NYESO-1-positive tumor cells. E, Cytolytic activity of chimeric TCR NK-92 cells against NYESO-1-positive tumor cells at different E: T ratios. F, Schematic experimental plan. Each NOD/SCID mouse subcutaneously received NYESO-1-positive tumor cells on day 0. NK-92 cells or chimeric TCR NK-92 cells (3 × 106 cells per mouse) were infused seven times. G, Tumor volume in NOD/SCID mice over time in chimeric TCR NK-92 cell group and NK-92 cell group (n = 5 per group, mean and SEM are shown). H, Tumor weight in NOD/SCID mice on day 54 following the inoculation of PDX tissue fragments in chimeric TCR NK-92 cell group and NK-92 cell group (n = 5 per group, mean and SEM are shown). All in vitro experiments were performed with at least three biological replicates, and data shown are representative of at least three independent experiments. The in vivo data are representative of two independent experiments. Data are presented as mean ± SEM. *** P < 0.001
    Primary Nk Cells T2 Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1908 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary nk cells t2 cell line/product/ATCC
    Average 97 stars, based on 1908 article reviews
    primary nk cells t2 cell line - by Bioz Stars, 2026-02
    97/100 stars

    Images

    1) Product Images from "TCR extracellular domain genetically linked to CD28, 2B4/41BB and DAP10/CD3 ζ -engineered NK cells mediates antitumor effects"

    Article Title: TCR extracellular domain genetically linked to CD28, 2B4/41BB and DAP10/CD3 ζ -engineered NK cells mediates antitumor effects

    Journal: Cancer Immunology, Immunotherapy : CII

    doi: 10.1007/s00262-022-03275-5

    The design and antitumor ability of chimeric TCR (TCR-28-2B10/BBζ) engineered NK-92 cells A, The chimeric TCR (TCR-28-2B10/BBζ) consisted of the extracellular domains of the TCR α and β chains specific for the HLA-A2-restricted NYESO-1-derived “SLLMWITQV” epitope (NYESO-1157-165 V) fused to the CD28 transmembrane domain (TM) followed by the 2B4 costimulatory domain and DAP10 signaling domain as well as the 41BB costimulatory domain and CD3ζ signaling domains, respectively. B, Representative flow cytometry of transduction efficiencies measured by staining chimeric TCR NK-92 cells and TCR NK-92 cells with an anti-murine TCR- β chain constant region antibody. C, IFN- γ ELISA measurement after coculture of chimeric TCR NK-92 cells and NK-92 cells with NYESO-1157-165 V epitope pulsed T2 cells. D, IFN- γ ELISA measurement after coculture of chimeric TCR NK-92 cells and NK-92 cells with NYESO-1-positive tumor cells. E, Cytolytic activity of chimeric TCR NK-92 cells against NYESO-1-positive tumor cells at different E: T ratios. F, Schematic experimental plan. Each NOD/SCID mouse subcutaneously received NYESO-1-positive tumor cells on day 0. NK-92 cells or chimeric TCR NK-92 cells (3 × 106 cells per mouse) were infused seven times. G, Tumor volume in NOD/SCID mice over time in chimeric TCR NK-92 cell group and NK-92 cell group (n = 5 per group, mean and SEM are shown). H, Tumor weight in NOD/SCID mice on day 54 following the inoculation of PDX tissue fragments in chimeric TCR NK-92 cell group and NK-92 cell group (n = 5 per group, mean and SEM are shown). All in vitro experiments were performed with at least three biological replicates, and data shown are representative of at least three independent experiments. The in vivo data are representative of two independent experiments. Data are presented as mean ± SEM. *** P < 0.001
    Figure Legend Snippet: The design and antitumor ability of chimeric TCR (TCR-28-2B10/BBζ) engineered NK-92 cells A, The chimeric TCR (TCR-28-2B10/BBζ) consisted of the extracellular domains of the TCR α and β chains specific for the HLA-A2-restricted NYESO-1-derived “SLLMWITQV” epitope (NYESO-1157-165 V) fused to the CD28 transmembrane domain (TM) followed by the 2B4 costimulatory domain and DAP10 signaling domain as well as the 41BB costimulatory domain and CD3ζ signaling domains, respectively. B, Representative flow cytometry of transduction efficiencies measured by staining chimeric TCR NK-92 cells and TCR NK-92 cells with an anti-murine TCR- β chain constant region antibody. C, IFN- γ ELISA measurement after coculture of chimeric TCR NK-92 cells and NK-92 cells with NYESO-1157-165 V epitope pulsed T2 cells. D, IFN- γ ELISA measurement after coculture of chimeric TCR NK-92 cells and NK-92 cells with NYESO-1-positive tumor cells. E, Cytolytic activity of chimeric TCR NK-92 cells against NYESO-1-positive tumor cells at different E: T ratios. F, Schematic experimental plan. Each NOD/SCID mouse subcutaneously received NYESO-1-positive tumor cells on day 0. NK-92 cells or chimeric TCR NK-92 cells (3 × 106 cells per mouse) were infused seven times. G, Tumor volume in NOD/SCID mice over time in chimeric TCR NK-92 cell group and NK-92 cell group (n = 5 per group, mean and SEM are shown). H, Tumor weight in NOD/SCID mice on day 54 following the inoculation of PDX tissue fragments in chimeric TCR NK-92 cell group and NK-92 cell group (n = 5 per group, mean and SEM are shown). All in vitro experiments were performed with at least three biological replicates, and data shown are representative of at least three independent experiments. The in vivo data are representative of two independent experiments. Data are presented as mean ± SEM. *** P < 0.001

    Techniques Used: Derivative Assay, Flow Cytometry, Transduction, Staining, Enzyme-linked Immunosorbent Assay, Activity Assay, In Vitro, In Vivo



    Similar Products

    primary nk cells t2 cell line  (ATCC)
    97
    ATCC primary nk cells t2 cell line
    The design and antitumor ability of chimeric TCR (TCR-28-2B10/BBζ) engineered NK-92 cells A, The chimeric TCR (TCR-28-2B10/BBζ) consisted of the extracellular domains of the TCR α and β chains specific for <t>the</t> <t>HLA-A2-restricted</t> NYESO-1-derived “SLLMWITQV” epitope (NYESO-1157-165 V) fused to the CD28 transmembrane domain (TM) followed by the 2B4 costimulatory domain and DAP10 signaling domain as well as the 41BB costimulatory domain and CD3ζ signaling domains, respectively. B, Representative flow cytometry of transduction efficiencies measured by staining chimeric TCR NK-92 cells and TCR NK-92 cells with an anti-murine TCR- β chain constant region antibody. C, IFN- γ ELISA measurement after coculture of chimeric TCR NK-92 cells and NK-92 cells with NYESO-1157-165 V epitope pulsed <t>T2</t> cells. D, IFN- γ ELISA measurement after coculture of chimeric TCR NK-92 cells and NK-92 cells with NYESO-1-positive tumor cells. E, Cytolytic activity of chimeric TCR NK-92 cells against NYESO-1-positive tumor cells at different E: T ratios. F, Schematic experimental plan. Each NOD/SCID mouse subcutaneously received NYESO-1-positive tumor cells on day 0. NK-92 cells or chimeric TCR NK-92 cells (3 × 106 cells per mouse) were infused seven times. G, Tumor volume in NOD/SCID mice over time in chimeric TCR NK-92 cell group and NK-92 cell group (n = 5 per group, mean and SEM are shown). H, Tumor weight in NOD/SCID mice on day 54 following the inoculation of PDX tissue fragments in chimeric TCR NK-92 cell group and NK-92 cell group (n = 5 per group, mean and SEM are shown). All in vitro experiments were performed with at least three biological replicates, and data shown are representative of at least three independent experiments. The in vivo data are representative of two independent experiments. Data are presented as mean ± SEM. *** P < 0.001
    Primary Nk Cells T2 Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary nk cells t2 cell line/product/ATCC
    Average 97 stars, based on 1 article reviews
    primary nk cells t2 cell line - by Bioz Stars, 2026-02
    97/100 stars
    		  Buy from Supplier

    Image Search Results


    The design and antitumor ability of chimeric TCR (TCR-28-2B10/BBζ) engineered NK-92 cells A, The chimeric TCR (TCR-28-2B10/BBζ) consisted of the extracellular domains of the TCR α and β chains specific for the HLA-A2-restricted NYESO-1-derived “SLLMWITQV” epitope (NYESO-1157-165 V) fused to the CD28 transmembrane domain (TM) followed by the 2B4 costimulatory domain and DAP10 signaling domain as well as the 41BB costimulatory domain and CD3ζ signaling domains, respectively. B, Representative flow cytometry of transduction efficiencies measured by staining chimeric TCR NK-92 cells and TCR NK-92 cells with an anti-murine TCR- β chain constant region antibody. C, IFN- γ ELISA measurement after coculture of chimeric TCR NK-92 cells and NK-92 cells with NYESO-1157-165 V epitope pulsed T2 cells. D, IFN- γ ELISA measurement after coculture of chimeric TCR NK-92 cells and NK-92 cells with NYESO-1-positive tumor cells. E, Cytolytic activity of chimeric TCR NK-92 cells against NYESO-1-positive tumor cells at different E: T ratios. F, Schematic experimental plan. Each NOD/SCID mouse subcutaneously received NYESO-1-positive tumor cells on day 0. NK-92 cells or chimeric TCR NK-92 cells (3 × 106 cells per mouse) were infused seven times. G, Tumor volume in NOD/SCID mice over time in chimeric TCR NK-92 cell group and NK-92 cell group (n = 5 per group, mean and SEM are shown). H, Tumor weight in NOD/SCID mice on day 54 following the inoculation of PDX tissue fragments in chimeric TCR NK-92 cell group and NK-92 cell group (n = 5 per group, mean and SEM are shown). All in vitro experiments were performed with at least three biological replicates, and data shown are representative of at least three independent experiments. The in vivo data are representative of two independent experiments. Data are presented as mean ± SEM. *** P < 0.001

    Journal: Cancer Immunology, Immunotherapy : CII

    Article Title: TCR extracellular domain genetically linked to CD28, 2B4/41BB and DAP10/CD3 ζ -engineered NK cells mediates antitumor effects

    doi: 10.1007/s00262-022-03275-5

    Figure Lengend Snippet: The design and antitumor ability of chimeric TCR (TCR-28-2B10/BBζ) engineered NK-92 cells A, The chimeric TCR (TCR-28-2B10/BBζ) consisted of the extracellular domains of the TCR α and β chains specific for the HLA-A2-restricted NYESO-1-derived “SLLMWITQV” epitope (NYESO-1157-165 V) fused to the CD28 transmembrane domain (TM) followed by the 2B4 costimulatory domain and DAP10 signaling domain as well as the 41BB costimulatory domain and CD3ζ signaling domains, respectively. B, Representative flow cytometry of transduction efficiencies measured by staining chimeric TCR NK-92 cells and TCR NK-92 cells with an anti-murine TCR- β chain constant region antibody. C, IFN- γ ELISA measurement after coculture of chimeric TCR NK-92 cells and NK-92 cells with NYESO-1157-165 V epitope pulsed T2 cells. D, IFN- γ ELISA measurement after coculture of chimeric TCR NK-92 cells and NK-92 cells with NYESO-1-positive tumor cells. E, Cytolytic activity of chimeric TCR NK-92 cells against NYESO-1-positive tumor cells at different E: T ratios. F, Schematic experimental plan. Each NOD/SCID mouse subcutaneously received NYESO-1-positive tumor cells on day 0. NK-92 cells or chimeric TCR NK-92 cells (3 × 106 cells per mouse) were infused seven times. G, Tumor volume in NOD/SCID mice over time in chimeric TCR NK-92 cell group and NK-92 cell group (n = 5 per group, mean and SEM are shown). H, Tumor weight in NOD/SCID mice on day 54 following the inoculation of PDX tissue fragments in chimeric TCR NK-92 cell group and NK-92 cell group (n = 5 per group, mean and SEM are shown). All in vitro experiments were performed with at least three biological replicates, and data shown are representative of at least three independent experiments. The in vivo data are representative of two independent experiments. Data are presented as mean ± SEM. *** P < 0.001

    Article Snippet: Cell lines and primary NK cells T2 cell line, a lymphoblastoid cell line deficient in TAP function whose HLA/A2 protein can be easily loaded with exogenous peptides, NK-92 and 293 T cell lines (human embryonic kidney cells, HEK) were obtained from the American Type Culture Collection.

    Techniques: Derivative Assay, Flow Cytometry, Transduction, Staining, Enzyme-linked Immunosorbent Assay, Activity Assay, In Vitro, In Vivo